Veozah Vms denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for veozah vms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC May Deny Veozah for VMS as Non-Formulary

Veozah (fezolinetant) may not appear on every UnitedHealthcare formulary tier, or may be placed on a non-preferred or non-covered tier depending on your specific plan. A non-formulary denial means UHC will not cover Veozah at the standard cost-sharing rate — and in some plans, will not cover it at all — because the plan's drug list does not include it at an accessible tier. This can occur because your plan was designed before Veozah was added to the national formulary, or because UHC's pharmacy benefit manager placed it on a restricted tier.

## Why This Is Appealable

Formulary exclusions are not absolute. Most UHC plans — and all ACA-compliant plans — include a formulary exception process. A formulary exception allows a non-formulary drug to be covered when no formulary alternative is clinically appropriate for the individual patient. For Veozah, the exception argument is strong when: hormone therapy alternatives are contraindicated or have failed; other non-hormonal formulary alternatives have been tried and were inadequate; or the patient's clinical profile makes the non-formulary drug the most appropriate option.

## Federal Appeal Framework

• Formulary exception request: This is the first step and is separate from, but often processed alongside, the formal appeal. Request an exception in writing, with clinical documentation. Decisions are typically required within 72 hours (expedited) or a short standard window.
• Internal appeal (ACA/ERISA §503): If the exception is denied, you have a full internal appeal right. UHC must provide the specific formulary criteria and the clinical basis for the denial.
• External review (ACA §2719): After a final internal denial, request independent external review within approximately four months. External reviewers evaluate whether the formulary decision was clinically appropriate given the individual's circumstances.

## Documentation to Gather

1. Formulary alternatives tried or contraindicated: For each formulary alternative UHC might suggest (hormone therapies, other non-hormonal agents), document either: (a) dates of trial and documented failure/intolerance, or (b) specific clinical reason the alternative is contraindicated or inappropriate. 2. Diagnosis and severity: Clinical documentation of menopause-related VMS with severity characterization sufficient to establish that treatment is warranted. 3. Unique clinical appropriateness of Veozah: The prescriber should explain why Veozah's non-hormonal, NK3-receptor mechanism is specifically appropriate for this patient — particularly if HT is contraindicated. 4. Prescriber medical-necessity letter: Addressing each formulary exception criterion in UHC's policy, referencing the FDA-approved prescribing label and the relevant professional society guideline (e.g., NAMS). 5. Plan documents: Obtain your plan's Summary of Benefits and Coverage (SBC) and the Evidence of Coverage to confirm the formulary exception process and deadlines.

## Criteria-Mapping Structure for Your Exception/Appeal Letter

| Formulary Exception Criterion | Your Documentation | |---|---| | No formulary alternative is clinically appropriate | List each alternative; document failure, intolerance, or contraindication with dates | | Patient has a condition requiring this specific drug | Diagnosis; severity; unique clinical feature distinguishing this patient | | Drug is FDA-approved for the requested indication | Confirm on-label use; attach or cite prescribing label | | Prescriber supports the exception | Letter from treating clinician with rationale |

Attach the prescribing label and relevant guideline excerpt to give the reviewer everything needed in one package.